TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
NEW YORK, Feb. 06, 2017 -- Safirstein Metcalf LLP announces that a class action lawsuit has been filed on behalf of investors who purchased TG Therapeutics, Inc. (“TG Therapeutics” or the “Company”) (NASDAQ:TGTX) securities between September 15, 2014 and October 12, 2016, inclusive (the “Class Period”).
If you purchased TG Therapeutics securities during the class period, and would like more information about getting involved in the TG Therapeutics Shareholder Class Action, please contact Safirstein Metcalf LLP at 1-800-221-0015, or email [email protected].
If you wish to serve as lead plaintiff, you must move the Court no later than March 7, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.
TG Therapeutics Shareholder Class Action
TICKER: TGTX
Common Stock CUSIP: 88322Q108
Class Period: September 15, 2014 – October 12, 2016
Lead Plaintiff Date: March 7, 2017
TG Therapeutics is a biopharmaceutical company that focuses on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.
According to the Complaint, defendants made false and/or misleading statements regarding the enrollment practices for the Company’s GENUINE Phase 3 trial. TG Therapeutics allegedly failed to disclose to investors that it failed to implement a proper screening protocol in the trial enrolling sites, that the Company was not enrolling patients at the required rate for the study to be completed on time, and that it would never get 330 enrolled patients in the study.
About Safirstein Metcalf LLP
Safirstein Metcalf LLP focuses its practice on shareholder rights. The law firm also practices in the areas of antitrust and consumer protection. All of the Firm’s legal endeavors are rooted in its core mission: provide investor and consumer protection.
Attorney advertising. Prior results do not guarantee a similar outcome.
Safirstein Metcalf LLP Peter Safirstein, Esq. 1250 Broadway 27th Floor New York, NY 10001 1-800-221-0015
